KPTI
Karyopharm Therapeutics Inc.
Key Financials
Net Income
$-196039000
↓ 156.5%
Revenue
$146.1M
↑ 0.6%
Operating Income
$-90707000
↑ 24.1%
EPS (Diluted)
$-17.93
↓ 1828.0%
Cash & Equivalents
$60.5M
↓ 3.1%
Total Assets
$108.4M
↓ 34.1%
Long-term Debt
$169.3M
N/A
Total Liabilities
$401.3M
↑ 14.5%
Recent SEC Filings
| Form Type | Filed Date | Link |
|---|---|---|
| SCHEDULE 13G/A | 4/13/2026 | View on SEC |
| ARS | 4/13/2026 | View on SEC |
| DEF 14A | 4/13/2026 | View on SEC |
| SCHEDULE 13G | 4/2/2026 | View on SEC |
| SCHEDULE 13G | 4/2/2026 | View on SEC |
| 8-K | 3/27/2026 | View on SEC |
| 8-K | 3/24/2026 | View on SEC |
| 4 | 3/3/2026 | View on SEC |
| 4 | 3/3/2026 | View on SEC |
| 4 | 3/3/2026 | View on SEC |
Company Information
| Field | Value |
|---|---|
| Ticker | KPTI |
| Company Name | Karyopharm Therapeutics Inc. |
| CIK | 1503802 |
| Sector | Pharmaceutical Preparations |
| Industry | Non-accelerated filer Smaller reporting company |
| Exchange | Nasdaq |
| SIC Code | 2834 |
| SIC Description | Pharmaceutical Preparations |
| Entity Type | operating |
| Fiscal Year End | 1231 |
| State of Incorporation | DE |
| Phone | 617-658-0600 |